Your browser doesn't support javascript.
loading
High serum cytokine levels may predict the responsiveness of patients with severe asthma to benralizumab.
Watanabe, Shizuka; Suzukawa, Maho; Tashimo, Hiroyuki; Ohshima, Nobuharu; Asari, Isao; Imoto, Sahoko; Kobayashi, Nobuyuki; Tohma, Shigeto; Nagase, Takahide; Ohta, Ken.
Afiliación
  • Watanabe S; Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
  • Suzukawa M; Department of Respiratory Medicine, University of Tokyo, Tokyo, Japan.
  • Tashimo H; Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
  • Ohshima N; Asthma, Allergy and Rheumatology Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
  • Asari I; Asthma, Allergy and Rheumatology Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
  • Imoto S; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
  • Kobayashi N; Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
  • Tohma S; Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
  • Nagase T; Department of Respiratory Medicine, University of Tokyo, Tokyo, Japan.
  • Ohta K; Asthma, Allergy and Rheumatology Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
J Asthma ; 59(8): 1604-1612, 2022 08.
Article en En | MEDLINE | ID: mdl-34121592
OBJECTIVE: Benralizumab, a humanized monoclonal antibody against human IL-5 receptor alpha, is effective in treating eosinophilic severe asthma. However, patients' response to benralizumab varies widely. In this study, we aimed to identify a new serum biomarker to accurately predict benralizumab response. METHODS: Seventeen benralizumab-treated patients with severe eosinophilic asthma were enrolled. Blood samples were collected; pulmonary function tests were performed and questionnaires were disseminated at baseline and after 1, 2, 4, and 6 months of treatment. Blood cytokine levels were measured. Response was defined as an elevation in forced expiratory volume in 1 s of at least 10.4% from baseline after 4 months of treatment. RESULTS: There were nine respondents and eight non-respondents. The non-responders showed significantly higher baseline serum interferon-γ; interleukin (IL)-4, -5, -6, -7, and -12p70; IL-17/IL-17A; IL-17E/IL-25; IL-18/IL-1F4; chemokine (C-C motif) ligand (CCL)3/macrophage inflammatory protein (MIP)-1α; CCL4/MIP-1ß; CCL11/eotaxin; matrix metalloproteinase-12; tumor necrosis factor-α, and thymic stromal lymphopoietin levels. After benralizumab administration, the serum CCL3/MIP-1α and CCL11/eotaxin levels significantly and persistently increased in the responders (CCL3/MIP-1α, responders: 144.5 ± 37.9 pg/ml (baseline) vs. 210.3 ± 59.4 pg/ml (4 months), p = 0.009; non-responders: 270.8 ± 139.8 pg/ml (baseline) vs. 299.5 ± 159.9 pg/ml (4 months), p = 0.33; CCL11/eotaxin, responders: 167.9 ± 62.6 pg/ml (baseline) vs. 326.7 ± 134.4 pg/ml (4 months), p = 0.038; non-responders: 420.9 ± 323.1 pg/ml (baseline) vs. 502.1 ± 406.0 pg/ml (4 months), p = 0.30). CONCLUSION: Low baseline serum inflammatory cytokine levels may be useful in predicting a good benralizumab response.Supplemental data for this article is available online at at www.tandfonline.com/ijas .
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Eosinofilia Pulmonar / Asma / Citocinas / Antiasmáticos / Anticuerpos Monoclonales Humanizados Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Asthma Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Eosinofilia Pulmonar / Asma / Citocinas / Antiasmáticos / Anticuerpos Monoclonales Humanizados Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Asthma Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido